Have a personal or library account? Click to login
Pharmacoresistant epilepsy associated with mutations in the KCNB1 and RELN genes. A case report Cover

Pharmacoresistant epilepsy associated with mutations in the KCNB1 and RELN genes. A case report

Journal of Epileptology
Volume 28 (2020): Issue 1 (December 2020)
By: Adamantios Katerelos,  Nikolaos Zagkos,  Dimitra Alexopoulou,  Stella Mouskou,  Anastasia Korona and  Emmanouil Manolakos  
Open Access
|Nov 2020

Authors

Adamantios Katerelos

ad_katerelos@yahoo.gr

Department of Neurology, “Karamandaneio”, Children’s Hospital, Patra, Greece

Nikolaos Zagkos

Department of Neurology, “Karamandaneio”, Children’s Hospital, Patra, Greece

Dimitra Alexopoulou

Department of Neurology, “Karamandaneio”, Children’s Hospital, Patra, Greece

Stella Mouskou

Department of Neurology, “P & A Kyriakou”, Children’s Hospital, Athens, Greece

Anastasia Korona

Department of Neurology, “P & A Kyriakou”, Children’s Hospital, Athens, Greece

Emmanouil Manolakos

Access To Genome, Clinical Laboratory Genetics, Athens-Thessaloniki, Greece
DOI: https://doi.org/10.21307/joepi-2020-006 | Journal eISSN: 2299-9728 | Journal ISSN: 2300-0147
Journal RSS Feed
Language: English
Page range: 73 - 77
Submitted on: Jul 31, 2020
Accepted on: Oct 15, 2020
Published on: Nov 25, 2020
Published by: The Foundation of Epileptology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
pharmacoresistant epilepsy,
KCNB1 gene,
RELN gene,
delayed speech
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other,
Neurology,
Pharmacology, toxicology,
Pharmacy,
Clinical pharmacy

© 2020 Adamantios Katerelos, Nikolaos Zagkos, Dimitra Alexopoulou, Stella Mouskou, Anastasia Korona, Emmanouil Manolakos, published by The Foundation of Epileptology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 28 (2020): Issue 1 (December 2020)Next article